米氮平联合帕罗西汀治疗抑郁症患者伴睡眠障碍的临床效果

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (554 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Mirtazapine combined with Paroxetine in the treatment of depressive patients with sleep disorder.Methods A total of 96 patients with depression with sleep disorder treated in Yingkou Fourth People's Hospital from January 2019 to January 2020 were selected as the research objects.They were divided into observation group(48 cases)and control group(48 cases)by random number table method.The control group was treated with Paroxetine,and the observation group was treated with Paroxetine combined with Mirtazapine.The clinical efficacy was compared between the two groups after treatment,and the scores of self-rating depression scale(SDS),Hamilton depression scale(HAMD)and Pittsburgh sleep quality index(PSQI)were compared between the two groups before and after treatment.Results The total effective rate of observation group(91.7%)was higher than that of control group(79.2%),and the difference was statistically significant(P＜0.05).After treatment,SDS score of observation group was lower than that in the control group,the difference was statistically significant(P＜0.05).HAMD score and PSQI score in the observation group were lower than those in the control group at 4 and 8 weeks after treatment,the differences were statistically significant(P＜0.05).Conclusion Mirtazapine combined with Paroxetine in the treatment of depressive patients with sleep disorder can effectively reduce depressive symptoms,improve depression mood and sleep quality,with significant clinical efficacy,worthy of clinical promotion.

Key words： Mirtazapine Paroxetine Depression Sleep disorders Randomized controlled study

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUAN Lei
	WANG Yanru

Cite this article:

LUAN Lei,WANG Yanru. Clinical effect of Mirtazapine combined with Paroxetine in the treatment of depressive patients with sleep disorder[J]. 中国当代医药, 2022, 29(10): 71-74.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I10/71

[1]	郭洪林，张月良，杨晓琴，等.西酞普兰联合米氮平对重度抑郁症伴睡眠障碍患者的睡眠质量、生活质量及氧化应激水平的影响[J].国际精神病学杂志，2018，45（5）：858-860，874.
[2]	尚立芝，毛梦迪，李耀洋，等.酸枣仁汤联合氟西汀治疗肝郁血虚型抑郁症伴失眠的临床观察[J/OL].中国实验方剂学杂志：1-7[2021-08-28].https://doi.org/10.13422/j.cnki.syfjx.20211402.
[3]	Hasin DS，Goodwin RD，Stinson FS，et al.Epidemiology of major depressive disorder：results from the National Epidemiologic Survey on Alcoholism and Related Condition[J].Arch Gen Psychiatry，2005，62（10）：1097-1106.
[4]	武玉萍.探讨米氮平与帕罗西汀治疗抑郁症伴睡眠障碍的疗效[J].中国现代药物应用，2017，11（19）：95-96.
[5]	郑计华，程华枝，严玮.米氮平与帕罗西汀治疗抑郁症伴睡眠障碍疗效对照分析[J].中国现代医生，2017，55（15）：95-97.
[6]	World Health Organization.The international statistical classification of diseases and related health problems，tenth revision（ICD-10）[M].Geneva：World Health Organization，1992.
[7]	国家中医药管理局.中药新药临床研究指导原则（试行）[S].北京：中国医药科技出版社，2002：216-220．
[8]	Li H，Jin D，Qiao F，et al.Relationship between the Self-Rating Anxiety Scale score and the success rate of 64-slice computed tomography coronary angiography[J].Int J Psychiatry Med，2016，51（1）：47-55.
[9]	刘燕朋，周进涛，连俊红.米氮平对抑郁症伴睡眠障碍患者抑郁症状、PSQI 评分及睡眠结构的影响[J].实用药物与临床，2018，21（12）：1398-1401.
[10]	杨哲，陆奕庭.米氮平联合艾司西酞普兰对抑郁症患者临床症状及睡眠障碍的影响分析[J].中国现代医药杂志，2018，20（12）：44-46.
[11]	Kaplan KA，Harvey AG.Hypersomnia across mood disorders：a review and synthesis[J].Sleep Med Rev，2009，13（4）：275-285.
[12]	Abad VC，Guilleminault C.Sleep and psychiatry[J].Dialogues Clin Neurosci，2005，7（4）：291-303.
[14]	Steiger A，Kimura M.Wake and sleep EEG provide biomarkers in depression[J].J Psychiatr Res，2010，44（4）：242-252.
[15]	张红梅，应琳琳.米氮平与帕罗西汀治疗156 例睡眠障碍伴抑郁症疗效对照分析[J].心理月刊，2019，14（14）：155.
[13]	Baglioni C，Battagliese G，Feige B，et al.Insomnia as a predictor of depression：a meta-analytic evaluation of longitudinal epidemiological studies[J].J Affect Disord，2011，135（1-3）：10-19.
[16]	孙福刚，陈雪莲，周海文，等.帕罗西汀联合奥氮平对抑郁症并发睡眠障碍患者心理状态及睡眠质量的影响[J].中国药物经济学，2021，16（3）：55-57，61.
[17]	于方舟，何茹.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍的效果观察[J].中国当代医药，2021，28（14）：103-106.
[18]	胡媚，李满连，陈毓茜，等.重复经颅磁刺激联合盐酸帕罗西汀在卒中后抑郁症患者中的应用[J].中国当代医药，2020，27（18）：63-65.
[19]	蔡文婷，赖燕，廖梅蓉，等.阿立派唑联合米氮平治疗躯体形式障碍患者的临床疗效及安全性研究[J].中国当代医药，2020，27（35）：82-85.
[20]	刘蓉.米氮平联合西酞普兰在抑郁症睡眠障碍患者治疗中的应用效果[J].中国医药科学，2020，10（2）：57-59.
[21]	Dolder CR，Nelson MH，Iler CA.The effects of mirtazapine on sleep in patients with major depressive disorder[J].Ann Clin Psychiatry，2012，24（3）：215.
[22]	蔡业清.阿戈美拉汀与米氮平治疗抑郁症伴睡眠障碍的效果对比[J].中国现代药物应用，2021，15（4）：28-30.
[23]	苏奎利.米氮平与帕罗西汀治疗抑郁症伴睡眠障碍疗效对照分析[J].心理月刊，2020，15（11）：114.
[24]	Sharpley AL，Attenburrow ME，Hafizi S，et al.Olanzapine increases slow wave sleep and sleep continuity in SSRIresistant depressed patients[J].J Clin Psychiatry，2005，66（4）：450-454.